Patrick Gray Joins MacroGenics as Vice President, Research; Appointed to Lead Discovery Efforts at Seattle Site.

Business Editors/Health & Medical Writers

ROCKVILLE, Md. & SEATTLE--(BW HealthWire)--July 24, 2002

MacroGenics, Inc., a private biotechnology company developing immunotherapeutics for cancer, autoimmune, and infectious diseases, announced the appointment of Dr. Patrick Gray, as Vice President, Research.

Dr. Gray, who will be based at the MacroGenics' site in Seattle, will be responsible for research discovery in Seattle and for managing the ongoing sponsored research collaborations with the Institute for Systems Biology.

"Pat is one of the rare breed of talented research scientists and managers who has been part of the biotechnology industry from the beginning," commented Dr. Scott Koenig, President and CEO. "He has participated in the growth of two leading biotechnology companies and still enjoys working at the bench. To have someone with his skills and experience in product development, greatly strengthens the senior management team at MacroGenics."

Dr. Gray began his active career in biotechnology in 1980 as one of the early scientists at Genentech, where he remained until 1989. After spending a year as a research fellow at Charing Cross in London, he joined the newly founded ICOS in Seattle in 1990, where he advanced to become Vice President, Science and finally left the company in 2001.

Among his accomplishments during the past 21 years were the cloning of the first hepatitis B surface antigen protein, interferon-gamma, multiple interferon-alpha genes, bacteriacidal permeability increasing protein, tumor necrosis factor-beta (TNF- beta), platelet activating factor acetylhydrolase, and macrophage-derived chemokine.

He is a co-author on 116 publications and a co-inventor on over 30 patents and patent applications, of which five of his inventions are either approved products or in later stage clinical testing. Pat received his B.S. with honors from the University of Oregon in Biology and his Ph.D. in Chemistry from the University of Colorado.

MacroGenics is focused on developing immune-based products for the treatment of cancer, infectious diseases, and autoimmune disorders.

In addition to exploiting discoveries in proteomics and genomics at the Seattle facility with founders, Drs. Lee Hood, Ruedi Aebersold, and Alan Aderem at the Institute for Systems Biology, the company is creating monoclonal antibody product candidates at its site in Rockville, MD, utilizing technology developed by founder, Dr. Jeffrey Ravetch of the Rockefeller University.

Last month, MacroGenics expanded its technology platform and product opportunities through the acquisition of Eliance, Inc, a vaccine discovery company in Dallas, Tx. The company will develop technology licensed from the University of Texas, Southwestern (UTSW), created in part by its founder, Dr. Stephen Johnston, Director of the Center for Biomedical Inventions (CBI).

To date, MacroGenics has raised over $26M from its investors including InterWest Partners, MPM Capital, OrbiMed Partners, Cogene Ventures, STARTech Early Ventures, Hunt Ventures, and Alexandria Realty Equities.